Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been granted patents related to the development of its prescription drug candidate CaPre in Israel, Mexico and Chile, the pharmaceutical company announced Wednesday.
CaPre is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.
Derived from krill oil, CaPre is primarily composed of certain omega-3 fatty acids that are thought to contribute to promote healthy heart, brain and visual function by reducing inflammation and types of fat known as triglycerides. Hypertriglyceridemia is an elevated level of that fat, or lipids, found in the blood.
The new patents, which are valid until 2030, relate to a concentrated phospholipid composition and method of using the same for modulating blood lipids, the company said in a statement.
“We are pleased to announce the granting of these latest patents, which further strengthen and expand the Acasti’s intellectual property portfolio,” said Pierre Lemieux, COO and CSO of Acasti.
According to Acasti, Israel, Mexico and Chile each represent important markets for potential commercialization of CaPre.
“The granting of these patents is another important milestone for Acasti and is in line with our commitment to build a global portfolio of patents to ensure long-lasting and comprehensive protection of our products,” Lemieux said in a statement.
Phase 3 testing underway
Phase 3 testing of CaPre is currently underway and will evaluate the safety and efficacy of the drug for the treatment of patients with severe hypertriglyceridemia. The study is a double-blind, placebo-controlled, 26-week, two-trial Phase 3 clinical program. Phase 1 and 2 are running in conjunction and will randomize a total of approximately 500 patients.
The program is being conducted at approximately 150 sites across the U.S., Canada and Mexico. Acasti anticipates reporting topline results by the end of 2019.
Shares of Acasti were trading at C$1.08 in Toronto and at US$0.81 in the US on Wednesday morning.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas